Dimension Inx is a Chicago-based biomaterials platform that designs, develops, and manufactures therapeutic products. The company works with biotech and medical device partners to solve materials problems and also internally develops products for applications ranging from bone regeneration to fertility preservation. Its lead product, CMFlex™, is a 3D-printed regenerative product that recently received U.S. FDA 510(k) clearance—the company's first such clearance. Dimension Inx intends to use its new funding to advance development of its therapeutics focused on functional organ restoration and to expand manufacturing capabilities. In the near term the company will use proceeds to support the commercial launch of CMFlex™. The company is led by CEO Caralynn Nowinski Collens. Dimension Inx develops regenerative medical implants and biofabrication systems to repair tissues and organs. Its core offering is a 3D-Painting Materials Design and Manufacturing System that the company says provides the versatility, manufacturability, and affordability necessary for widespread adoption of tissue-engineered regenerative medical products. The firm is described as an emerging leader in biofabrication in medicine. Dimension Inx is based in Chicago, IL. The company closed a $3.175M Series Seed financing led by KdT Ventures, with participation from Better Ventures and Revolution's Rise of the Rest Seed Fund.

Total raised

$15M

Funding rounds

2

Latest round

Series A

Latest activity

Feb 2023